Skip to main content
TLSA
NASDAQ Life Sciences

Tiziana Life Sciences Completes Dosing in Phase 2a MS Trial; Topline Data Expected Late Q3/Early Q4 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.12
Mkt Cap
$143.706M
52W Low
$1.04
52W High
$2.6
52W Position info
7.7% above low
Off High info
57% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

TLSA is trading near its 52-week low of $1.04 (7.7% above the low) on light trading volume (0.4× avg).

Summary

Tiziana Life Sciences announced the completion of dosing for all patients in its Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis, with topline data expected in late Q3/early Q4 2026.


Key Events · Product Development and Regulatory · TLSA

  • Last Patient Dosed in Phase 2a Trial

    All patients in the INFORM-MS Phase 2a clinical trial for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis have received their first dose.

  • Topline Data Anticipated

    Topline data from the trial is expected in late Q3/early Q4 of 2026 and will be presented at the ACTRIMS/ECTRIMS meeting in October 2026.

  • Trial Progress for Lead Candidate

    This milestone advances the development of intranasal foralumab, the company's lead candidate, which is the only fully human anti-CD3 monoclonal antibody in clinical development delivered intranasally.


Analysis · TLSA · Life Sciences

This 6-K announces a critical operational milestone for Tiziana Life Sciences, confirming that all patients in its Phase 2a INFORM-MS trial for intranasal foralumab have received their first dose. This progress is vital for the company, especially following a recent 'going concern' warning, and sets the stage for the highly anticipated topline data readout in late Q3/early Q4 2026. The successful completion of dosing de-risks the trial timeline and maintains momentum for their lead candidate in a condition with limited treatment options.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLSA was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.7M. The 52-week trading range was $1.04 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Nov 05, 2026, 2:26 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.6249
Real-time Price: $0.6289 info
Change: +$0.0040 (+0.64%) info
Market Cap: $79.911M info
TLSA
Nov 02, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.6289 info
Change: -$0.2611 (-29%) info
Market Cap: $79.911M info
TLSA
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.8685
Real-time Price: $0.6289 info
Change: -$0.2396 (-28%) info
Market Cap: $79.911M info
TLSA
Oct 16, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.6289 info
Change: -$0.4211 (-40%) info
Market Cap: $79.911M info
TLSA
Oct 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.6289 info
Change: -$0.4411 (-41%) info
Market Cap: $79.911M info